275 related articles for article (PubMed ID: 24233555)
21. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
Han TH; Chen R; Advani R; Berryman RB; Smith SE; Forero-Torres A; Rosenblatt JD; Smith MR; Zain J; Hunder NN; Engert A
Cancer Chemother Pharmacol; 2013 Jul; 72(1):241-9. PubMed ID: 23719719
[TBL] [Abstract][Full Text] [Related]
23. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
[TBL] [Abstract][Full Text] [Related]
24. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
[TBL] [Abstract][Full Text] [Related]
25. CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
Hansen HP; Trad A; Dams M; Zigrino P; Moss M; Tator M; Schön G; Grenzi PC; Bachurski D; Aquino B; Dürkop H; Reiners KS; von Bergwelt-Baildon M; Hallek M; Grötzinger J; Engert A; Paes Leme AF; Pogge von Strandmann E
Oncotarget; 2016 May; 7(21):30523-35. PubMed ID: 27105521
[TBL] [Abstract][Full Text] [Related]
26. Immunologic targeting of CD30 eliminates tumourigenic human pluripotent stem cells, allowing safer clinical application of hiPSC-based cell therapy.
Sougawa N; Miyagawa S; Fukushima S; Kawamura A; Yokoyama J; Ito E; Harada A; Okimoto K; Mochizuki-Oda N; Saito A; Sawa Y
Sci Rep; 2018 Feb; 8(1):3726. PubMed ID: 29487310
[TBL] [Abstract][Full Text] [Related]
27. CD30 is a potential therapeutic target in malignant mesothelioma.
Dabir S; Kresak A; Yang M; Fu P; Wildey G; Dowlati A
Mol Cancer Ther; 2015 Mar; 14(3):740-6. PubMed ID: 25589494
[TBL] [Abstract][Full Text] [Related]
28. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
Bossard C; Dobay MP; Parrens M; Lamant L; Missiaglia E; Haioun C; Martin A; Fabiani B; Delarue R; Tournilhac O; Delorenzi M; Gaulard P; de Leval L
Blood; 2014 Nov; 124(19):2983-6. PubMed ID: 25224410
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.
Lamarque M; Bossard C; Contejean A; Brice P; Parrens M; Le Gouill S; Brière J; Bouabdallah R; Canioni D; Tilly H; Bouchindhomme B; Bachy E; Delarue R; Haioun C; Gaulard P
Haematologica; 2016 Mar; 101(3):e103-6. PubMed ID: 26703966
[No Abstract] [Full Text] [Related]
31. Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.
Wang CC; Thanh C; Gibson EA; Ball-Burack M; Hogan LE; Descours B; Jones N; Carvidi AB; Munter S; Bakkour S; Busch MP; Milush JM; Deeks SG; Henrich TJ
Blood Adv; 2018 Dec; 2(23):3479-3482. PubMed ID: 30530753
[TBL] [Abstract][Full Text] [Related]
32. IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.
Bauer K; Hadzijusufovic E; Cerny-Reiterer S; Hoermann G; Reifinger M; Pirker A; Valent P; Willmann M
Vet Comp Oncol; 2017 Dec; 15(4):1240-1256. PubMed ID: 27507155
[TBL] [Abstract][Full Text] [Related]
33. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30.
Hogan LE; Vasquez J; Hobbs KS; Hanhauser E; Aguilar-Rodriguez B; Hussien R; Thanh C; Gibson EA; Carvidi AB; Smith LCB; Khan S; Trapecar M; Sanjabi S; Somsouk M; Stoddart CA; Kuritzkes DR; Deeks SG; Henrich TJ
PLoS Pathog; 2018 Feb; 14(2):e1006856. PubMed ID: 29470552
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
35. Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
Zhao B; Chen R; O'Connor OA; Gopal AK; Ramchandren R; Goy A; Matous JV; Fasanmade AA; Manley TJ; Han TH
Br J Clin Pharmacol; 2016 Sep; 82(3):696-705. PubMed ID: 27115790
[TBL] [Abstract][Full Text] [Related]
36. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
[TBL] [Abstract][Full Text] [Related]
37. Targeting CD30 in anaplastic large cell lymphoma.
Vadakara J; Pro B
Curr Hematol Malig Rep; 2012 Dec; 7(4):285-91. PubMed ID: 23065407
[TBL] [Abstract][Full Text] [Related]
38. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR
Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199
[TBL] [Abstract][Full Text] [Related]
39. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
40. CD30 as a therapeutic target in adult haematological malignancies: Where are we now?
Veyri M; Spano JP; Le Bras F; Marcelin AG; Todesco E
Br J Haematol; 2023 Jun; 201(6):1033-1046. PubMed ID: 37170397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
